Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Liver transplantation in the setting of chronic HCV.

Terrault N.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):531-48. doi: 10.1016/j.bpg.2012.09.010. Review.

PMID:
23199510
2.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
3.

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2004 Feb;10(2):199-207.

4.

Treatment of chronic hepatitis C virus infection after liver transplantation.

Agarwal K, Barnabas A.

Dig Liver Dis. 2013 Sep 30;45 Suppl 5:S349-54. doi: 10.1016/j.dld.2013.07.014. Review.

PMID:
24091115
5.

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.

Asselah T.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):455-62. doi: 10.1016/j.bpg.2012.09.003.

PMID:
23199504
6.

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.

Saxena V, Terrault N.

Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64. Review.

PMID:
22476221
7.

Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.

Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D.

Liver Transpl. 2008 Dec;14(12):1766-77. doi: 10.1002/lt.21635.

8.

[Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis].

Yuan XL, Li MY, Zhang DZ.

Zhonghua Gan Zang Bing Za Zhi. 2012 May;20(5):357-62. doi: 10.3760/cma.j.issn.1007-3418.2012.05.011. Chinese.

PMID:
22971281
9.

Hepatitis C virus and liver transplantation.

Ahmed A, Keeffe EB.

Clin Liver Dis. 2001 Nov;5(4):1073-90. Review.

PMID:
11685796
10.

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.

Esteban R, Buti M.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):445-53. doi: 10.1016/j.bpg.2012.09.001. Review.

PMID:
23199503
11.

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.

Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83. doi: 10.1097/MEG.0b013e3282f762f8.

PMID:
18617783
12.

Management of hepatitis C infection before and after liver transplantation.

Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L.

World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447. Review.

13.

Telaprevir: an oral protease inhibitor for hepatitis C virus infection.

Kim JJ, Culley CM, Mohammad RA.

Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33. doi: 10.2146/ajhp110123. Review.

PMID:
22180548
14.

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.

Roche B, Coilly A, Roque-Afonso AM, Samuel D.

Viruses. 2015 Sep 23;7(9):5155-68. doi: 10.3390/v7092864. Review.

15.

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Peveling-Oberhag J, Zeuzem S, Hofmann WP.

Med Microbiol Immunol. 2010 Feb;199(1):1-10. doi: 10.1007/s00430-009-0131-8. Epub 2009 Nov 10. Review.

PMID:
19902246
16.

[Direct antiviral treatment strategies in chronic hepatitis C].

Neumann-Haefelin C, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2012 Jun;137(25-26):1360-5. doi: 10.1055/s-0032-1305064. Epub 2012 May 31. Review. German.

PMID:
22653493
17.

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.

Zylberberg H, Benhamou Y, Lagneaux JL, Landau A, Chaix ML, Fontaine H, Bochet M, Poynard T, Katlama C, Pialoux G, Bréchot C, Pol S.

Gut. 2000 Nov;47(5):694-7.

18.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
19.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
20.

[Treatment of recurrent HCV infection after liver transplantation].

Kanizaj TF, Colić-Cvrlje V, Mrzljak A, Ostojić R.

Acta Med Croatica. 2013 Oct;67(4):373-81. Croatian.

PMID:
24984339

Supplemental Content

Support Center